Viral Hepatitis

WASHINGTON — Although adenovirus infection has been widely implicated in an outbreak of acute, severe hepatitis in children, data presented at The Liver Meeting found no “singular definitive etiology” for these cases.

The FDA has updated the label indication for 25 mg tenofovir alafenamide for the treatment of chronic hepatitis B virus with compensated liver disease, expanding the patient population to include children aged 12 years older.

July 28 is World Hepatitis Day, and this year’s theme, “I can’t wait,” emphasizes the importance of testing and treatment and the need for greater global response to viral hepatitis elimination efforts.

Among pregnant women hospitalized for delivery, those who were incarcerated had higher rates of adverse pregnancy outcomes and medical conditions, according to a cross-sectional analysis in the American Journal of Obstetrics & Gynecology.

WHO released the first-ever global guidance for countries seeking validated hepatitis B virus and hepatitis C virus elimination.

Routine testing for bloodborne viruses in EDs proved easily integrated and cost-effective in the U.K., according to a presentation at The International Liver Congress.

May is Hepatitis Awareness Month in the United States, and May 19 is Hepatitis Testing Day.

Tenofovir alafenamide fumarate prevented mother to child transmission of hepatitis B without any safety concerns, according to study results.

Patients with hepatitis B treated with an investigational RNAi drug experienced reduced levels of surface antigens across different dose levels, according to research presented at The Digital International Liver Congress.

There are many people in the United States living with viral hepatitis, which can lead to liver health problems such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.